

	Particulars	STANDALONE					Year Ended March-12
		Quarter Ended			Six Months		
		September-12	June-12	September-11	September-12	September-11	
	PART- I	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
1	(a) Net Sales / Income from Operations						
	Domestic	28,913	22,870	24,902	51,783	45,625	87,718
	Exports	11,840	11,200	13,616	23,039	25,167	49,961
	Total	40,753	34,070	38,518	74,822	70,792	137,679
	Less : Excise Duty	173	199	109	372	254	554
	Net Sales / Income from Operations	40,580	33,871	38,409	74,450	70,538	137,125
	(b) Other Operating Income	105	70	103	175	143	404
	Total Income from Operations	40,685	33,941	38,512	74,624	70,681	137,528
2	Expenses						
	(a) Decrease/(increase) in stock in trade and work in progress	1,949	(142)	(2,085)	1,807	(3,259)	(6,444)
	(b) Consumption of Raw Materials & Packing Materials	12,631	11,168	15,422	23,799	27,224	52,824
	(c) Purchase of traded goods	4,277	4,068	4,841	8,345	9,397	16,779
	(d) Employees' Cost	4,855	4,495	4,037	9,350	8,211	16,846
	(e) Research and Development Expense	1,603	1,389	1,460	2,991	2,669	5,858
	(f) Excise Duty	117	114	243	232	235	509
	(g) Other Expenditure	8,898	8,021	8,544	16,919	15,224	30,200
	Total Expenses	34,330	29,113	32,462	63,442	59,701	116,571
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	6,355	4,828	6,050	11,182	10,980	20,957
4	Other Income	22	22	10	44	18	44
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	6,377	4,850	6,060	11,226	10,998	21,001
6	Depreciation	882	866	845	1,747	1,664	3,365
7	Interest (Net)	312	574	708	886	1,385	2,621
8	Net Profit / (Loss) from Ordinary Activities before Tax	5,183	3,410	4,507	8,593	7,949	15,015
9	Tax Expense						
	Less : Provision for Current Tax	1,042	687	917	1,729	1,628	3,000
	Less /Add : Provision for Deferred Tax Liability/(Assets)	(6)	(5)	(210)	(11)	(142)	(38)
10	Net Profit / (Loss) from Ordinary Activities after Tax	4,147	2,728	3,800	6,875	6,463	12,054
11	Paid up Equity Share Capital (Face value of share ₹ 2/-)	3,770	3,770	3,770	3,770	3,770	3,770
12	Reserves excluding Revaluation Reserve						32,316
13	Debenture Redemption Reserve						3,125
14	Basic & Diluted EPS (Not Annualised)	2.20	1.45	2.02	3.65	3.43	6.39
15	Debt Equity Ratio	-	-	-	0.69	1.37	1.02
16	Debt Service Coverage Ratio	-	-	-	3.59	2.04	2.91
17	Interest Service Coverage Ratio	-	-	-	15.44	7.94	11.76
	PART- II						
A	Particulars of Shareholding						
1	Public Shareholding						
	- Number of Shares	48777294	48777294	48763089	48777294	48763089	48763089
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding						
	- Fully Non - Encumbered						
	- Number of Shares	139738620	139738620	139752825	139738620	139752825	139752825
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS						
				Quarter ended on 30th September, 2012			
	Pending at the beginning of the quarter			NIL			
	Received during the quarter			NIL			
	Disposed of during the quarter			NIL			
	Remaining unresolved at the end of the quarter			NIL			

Notes :

- 1 The above results, which includes unaudited results of the Subsidiary, have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 19th October 2012

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com

Particulars	CONSOLIDATED					
	Quarter Ended			Six Months		Year Ended
	September-12	June-12	September-11	September-12	September-11	March-12
PART- I	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
1 (a) Net Sales / Income from Operations						
Domestic	28,913	22,870	24,902	51,783	45,625	87,718
Exports	11,840	13,936	14,903	25,776	28,652	59,071
Total	40,753	36,806	39,805	77,559	74,277	146,789
Less : Excise Duty	173	199	109	372	254	554
Net Sales / Income from Operations	40,580	36,607	39,696	77,187	74,023	146,235
(b) Other Operating Income	105	70	103	175	143	404
Total Income from Operations	40,685	36,677	39,799	77,362	74,166	146,639
2 Expenses						
(a) Decrease/(increase) in stock in trade and work in progress	1,949	(142)	(2,085)	1,807	(3,259)	(6,444)
(b) Consumption of Raw Materials & Packing Materials	12,631	11,168	15,422	23,799	27,224	52,824
(c) Purchase of traded goods	4,277	6,415	6,038	10,692	12,583	24,412
(d) Employees' Cost	4,855	4,495	4,037	9,350	8,211	16,846
(e) Research and Development Expense	1,603	1,389	1,460	2,991	2,669	5,858
(f) Excise Duty	117	114	243	232	235	509
(g) Other Expenditure	8,783	8,011	8,637	16,794	15,421	30,593
Total Expenses	34,215	31,450	33,752	65,663	63,084	124,597
3 Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	6,470	5,227	6,047	11,698	11,082	22,041
4 Other Income	22	22	10	44	18	44
5 Profit/ (Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	6,492	5,249	6,057	11,742	11,100	22,086
6 Depreciation	882	866	845	1,748	1,664	3,365
7 Interest (Net)	312	574	708	886	1,385	2,621
8 Net Profit / (Loss) from Ordinary Activities before Tax	5,298	3,809	4,504	9,108	8,051	16,099
9 Tax Expense						
Less : Provision for Current Tax	1,055	731	910	1,786	1,633	3,123
Less/(Add) : Provision for Deferred Tax Liability /(Assets)	(6)	(5)	(210)	(11)	(142)	(38)
10 Net Profit / (Loss) from Ordinary Activities after Tax	4,249	3,083	3,804	7,333	6,560	13,014
11 Paid up Equity Share Capital (Face value of share ₹ 2/-)	3,770	3,770	3,770	3,770	3,770	3,770
12 Reserves excluding Revaluation Reserve						35,730
13 Debenture Redemption Reserve						3,125
14 Basic & Diluted EPS (Not Annualised)	2.25	1.64	2.02	3.89	3.48	6.90
15 Debt Equity Ratio	-	-	-	0.64	1.30	0.94
16 Debt Service Coverage Ratio	-	-	-	3.79	2.06	3.06
17 Interest Service Coverage Ratio	-	-	-	16.31	8.01	12.40
PART- II						
A Particulars of Shareholding						
1 Public Shareholding						
- Number of Shares	48777294	48777294	48763089	48777294	48763089	48763089
- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
2 Promoters and Promoter Group Shareholding						
- Fully Non - Encumbered						
- Number of Shares	139738620	139738620	139752825	139738620	139752825	139752825
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
B INVESTOR COMPLAINTS						
				Quarter ended on 30th September, 2012		
Pending at the beginning of the quarter				NIL		
Received during the quarter				NIL		
Disposed of during the quarter				NIL		
Remaining unresolved at the end of the quarter				NIL		

Notes :

- 1 The above results, which includes unaudited results of the Subsidiary, have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 19th October 2012

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com